Abstract A010: Evaluation of the Avantect Pancreatic Cancer Test for identifying high-risk pancreatic cysts

Anna Bergamaschi,David Haan,Verena Friedl,Gulfem Guler,Michael Kesling,Micah Collins,Kyle Hazen,Vanessa Lopez,Roger Malta,Maryam Nabiyouni,Michael Riviere,Anna Leighton,Melissa Peters,Shimul Chowdhury,Wayne Volkmuth,Samuel Levy
DOI: https://doi.org/10.1158/1538-7445.panca2023-a010
IF: 11.2
2024-01-16
Cancer Research
Abstract:Abstract Background: Pancreatic cystic lesions are common incidental findings on imaging, but up to half may be precursors of pancreatic cancer. Current diagnostic methods cannot robustly identify cysts that have the highest probability to progress to cancer and require treatment. To address this gap, we evaluated the performance of a non-invasive epigenomic based test employing cell-free DNA, the Avantect Pancreatic Cancer test, in a cohort of patients with pancreatic cysts to identify those at higher risk of malignancy. Methods: In this study, we investigated the use of Avantect in a cohort of patients with pancreatic cysts. Whole blood was collected from 44 patients with cysts: 18 patients with high/moderate and 26 patients with low grade dysplasia/benign cysts. In parallel, demographic information, imaging results, surgical reports, and histological findings were collected for analysis and clinical annotation of patients. Results: Avantect was successfully run on all 44 pancreatic cysts. 16 out of the 18 (89%) patients with cysts of moderate/high grade dysplasia were detected having an abnormal pancreatic signal associated with pancreatic cancer. Of the 26 patients with cysts with low grade/benign features 8 (31%) were detected by Avantect as abnormal. This nearly three-fold higher detection rate for abnormal pancreatic signals in patients with cysts with medium/high grade dysplasia suggests the detection of epigenomic changes as precursors to pancreatic cancer. Conclusions: The Avantect Pancreatic Cancer test shows initial promise in distinguishing between low grade/benign and moderate/high grade dysplasia cysts. Larger studies have been commenced to enable prospective evaluation of Avantect for the management and surveillance of individuals with pancreatic cysts. Citation Format: Anna Bergamaschi, David Haan, Verena Friedl, Gulfem Guler, Michael Kesling, Micah Collins, Kyle Hazen, Vanessa Lopez, Roger Malta, Maryam Nabiyouni, Michael Riviere, Anna Leighton, Melissa Peters, Shimul Chowdhury, Wayne Volkmuth, Samuel Levy. Evaluation of the Avantect Pancreatic Cancer Test for identifying high-risk pancreatic cysts [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr A010.
oncology
What problem does this paper attempt to address?